PhotoCure ASA (LTS:0IMT) Other Current Receivables: kr24.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IMT PhotoCure ASA LTS:0IMT
70 GF Score
Price kr58.20
GF Value kr75.08
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Other Current Receivables?

PhotoCure ASA LTS:0IMT 70 Other Current Receivables is kr24.7 Mil as of Mar. 2026. GuruFocus rates LTS:0IMT with a GF Score™ of 70/100 and a GF Value™ of kr75.08 (Modestly Undervalued). The stock has 1 warning sign investors should review.

PhotoCure ASA's Other Current Receivables for the quarter that ended in Mar. 2026 was kr24.7 Mil.

PhotoCure ASA's quarterly Other Current Receivables declined from Sep. 2025 (kr22.86 Mil) to Dec. 2025 (kr7.68 Mil) but then increased from Dec. 2025 (kr7.68 Mil) to Mar. 2026 (kr24.68 Mil).

PhotoCure ASA's annual Other Current Receivables increased from Dec. 2023 (kr4.68 Mil) to Dec. 2024 (kr5.37 Mil) and increased from Dec. 2024 (kr5.37 Mil) to Dec. 2025 (kr7.68 Mil).

PhotoCure ASA Other Current Receivables Related Terms

PhotoCure ASA Other Current Receivables Historical Data

* Premium members only.

The historical data trend for PhotoCure ASA's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhotoCure ASA Other Current Receivables Chart

PhotoCure ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.93 7.34 4.68 5.37 7.68

PhotoCure ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.26 20.52 22.86 7.68 24.68
LTS:0IMT
70GF Score
PhotoCure ASA LTS:0IMT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhotoCure ASA Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr24.7 Mil mean?
PhotoCure ASA (LTS:0IMT) has a Other Current Receivables of kr24.7 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on PhotoCure ASA and its competitors.
Is PhotoCure ASA's Other Current Receivables too high?
PhotoCure ASA's current Other Current Receivables is kr24.7 Mil. Overall, PhotoCure ASA has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Other Current Receivables compare to ZTS and UTHR?
PhotoCure ASA's Other Current Receivables of kr24.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on PhotoCure ASA and its competitors. PhotoCure ASA's current Other Current Receivables is kr24.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (LTS:0IMT) is currently considered Modestly Undervalued. The stock's GF Value™ is kr75.08, compared to a current price of kr58.20 — trading 22.5% below its estimated fair value. The current Other Current Receivables is kr24.7 Mil. PhotoCure ASA's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For PhotoCure ASA (LTS:0IMT), the current Other Current Receivables is kr24.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (LTS:0IMT) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of kr58.20 is trading 22.5% below its estimated GF Value™ of kr75.08. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for LTS:0IMT:

  • Other Current Receivables: kr24.7 Mil
  • GF Value™: kr75.08 vs. price of kr58.20 (22.5% below fair value)
  • GF Score™: 70/100 with 1 warning sign

No single metric tells the full story. See the LTS:0IMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
70GF Score

Get the complete analysis for LTS:0IMT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr58.20
Price
kr75.08
GF Value